Department of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden.
Section of Clinical Bacteriology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Infect Dis (Lond). 2022 Sep;54(9):623-631. doi: 10.1080/23744235.2022.2071461. Epub 2022 May 9.
This study aimed to investigate what impact the COVID-19 pandemic and its associated restrictions had on and infections in Sweden, Denmark and Norway, countries with very different governmental strategies for handling this pandemic.
Retrospective analysis of data collected requests to Swedish regions and to health authorities in Denmark and Norway. The data were collected for the years 2018-2020 and the data from Sweden were more detailed.
When the pandemic restrictions were installed in 2020, the number of reported chlamydia cases decreased. The decline was most pronounced in Norway 10.8% (2019: = 28,446; 2020: = 25,444) while it was only 3.1% in Denmark (2019: = 35,688; 2020: = 34,689) and 4.3% in Sweden (2019: = 34,726; 2020: = 33,339). Nucleic acid amplifications tests for chlamydia decreased in Sweden (10%) and Norway (18%) in 2020 compared to 2019, while in Denmark a 21% decrease was noted in April 2020 but thereafter increased to a higher level than 2019. The number of reported gonorrhoea cases decreased in Sweden (17%) and in Norway (39%) in 2020 compared to 2019, while a 21% increase was noted in Denmark.
Pandemic restrictions had an impact on the number of reported chlamydia infections in all three countries, but only temporarily and did not seem to be correlated to the restriction levels. The number of reported gonorrhoea infections in Sweden and Norway significantly decreased but not in Denmark. Pandemic restrictions appear to have had a limited effect on the spread of chlamydia and gonorrhoea.
本研究旨在探讨 COVID-19 大流行及其相关限制措施对瑞典、丹麦和挪威三国衣原体和淋病感染的影响。这三个国家在处理大流行方面采取了非常不同的政府策略。
对瑞典各地区、丹麦和挪威卫生当局收集的 2018-2020 年数据进行回顾性分析。瑞典的数据更为详细。
2020 年大流行限制措施实施后,报告的衣原体病例数量减少。挪威的降幅最为显著(10.8%,2019 年:=28446;2020 年:=25444),而丹麦仅为 3.1%(2019 年:=35688;2020 年:=34689),瑞典为 4.3%(2019 年:=34726;2020 年:=33339)。2020 年,瑞典(10%)和挪威(18%)的衣原体核酸扩增检测较 2019 年减少,而丹麦在 2020 年 4 月减少了 21%,但此后增加到高于 2019 年的水平。2020 年,瑞典(17%)和挪威(39%)的淋病报告病例数较 2019 年减少,而丹麦则增加了 21%。
大流行限制措施对三国报告的衣原体感染数量产生了影响,但只是暂时的,且似乎与限制水平无关。瑞典和挪威报告的淋病感染数量显著减少,但丹麦并非如此。大流行限制措施似乎对衣原体和淋病的传播影响有限。